
Mads Agerbaek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9059434/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1221-1230.	1.2	4
2	Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in newly orchiectomized testicular cancer patients. Brain Imaging and Behavior, 2022, 16, 199-210.	1.1	5
3	Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer. European Urology Oncology, 2022, 5, 203-213.	2.6	14
4	Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen. Bladder Cancer, 2022, 8, 71-80.	0.2	4
5	Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study. Journal of Cancer Survivorship, 2021, 15, 509-517.	1.5	15
6	Adverse health behaviours in long-term testicular cancer survivors: a Danish nationwide study. Acta Oncológica, 2021, 60, 361-369.	0.8	4
7	Genome-wide circulating tumor DNA monitoring for bladder cancer treatment management and organ preservation Journal of Clinical Oncology, 2021, 39, e16527-e16527.	0.8	0
8	Cognitive changes and brain connectomes, endocrine status, and risk genotypes in testicular cancer patients–A prospective controlled study. Cancer Medicine, 2021, 10, 6249-6260.	1.3	3
9	Reply to: Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy. Nature Communications, 2021, 12, 4834.	5.8	3
10	Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation. Clinical Epidemiology, 2021, Volume 13, 871-882.	1.5	1
11	Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer. European Urology Focus, 2020, 6, 711-719.	1.6	9
12	Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). European Journal of Cancer, 2020, 127, 173-182.	1.3	16
13	Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. Journal of Clinical Oncology, 2020, 38, 584-592.	0.8	52
14	Psychological stress in long-term testicular cancer survivors: a Danish nationwide cohort study. Journal of Cancer Survivorship, 2020, 14, 72-79.	1.5	12
15	Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. Acta Oncológica, 2020, 59, 1374-1381.	0.8	8
16	Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nature Communications, 2020, 11, 4858.	5.8	124
17	GCT-65. INCIDENCE AND OUTCOME OF INTRACRANIAL MALIGNANT GERM CELL TUMOURS DIAGNOSED IN WESTERN DENMARK IN THE LAST DECADE. Neuro-Oncology, 2020, 22, iii341-iii341.	0.6	0
18	Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial. Oncologist, 2019, 24, 745-e213.	1.9	7

#	Article	IF	CITATIONS
19	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology, 2019, 37, 1547-1557.	0.8	298
20	Abstract 913: Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. , 2019, , .		3
21	Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Scientific Reports, 2018, 8, 1917.	1.6	50
22	Limited post-chemotherapy retroperitoneal resection of residual tumour in non-seminomatous testicular cancer: complications, outcome and quality of life. Acta Oncológica, 2018, 57, 1084-1093.	0.8	11
23	Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. European Urology, 2018, 73, 535-540.	0.9	112
24	Cohort Profile: The Danish Testicular Cancer Late Treatment Effects Cohort (DaTeCa-LATE). Frontiers in Oncology, 2018, 8, 37.	1.3	13
25	Sexual Function in a Nationwide Cohort of 2,260 Survivors of Testicular Cancer after 17 Years of Followup. Journal of Urology, 2018, 200, 794-800.	0.2	22
26	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. European Urology, 2017, 71, 961-969.	0.9	154
27	Surveillance versus adjuvant radiotherapy for patients with highâ€risk stage I seminoma. Cancer, 2017, 123, 1212-1218.	2.0	36
28	Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy. Journal of the National Cancer Institute, 2017, 109, .	3.0	66
29	Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study. European Urology, 2017, 71, 290-298.	0.9	59
30	Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging and Behavior, 2017, 11, 769-783.	1.1	65
31	The Danish Testicular Cancer database. Clinical Epidemiology, 2016, Volume 8, 703-707.	1.5	21
32	Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer. JAMA Oncology, 2016, 2, 1624.	3.4	77
33	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. European Urology, 2016, 70, 75-82.	0.9	174
34	Late Relapses in Stage I Testicular Cancer Patients on Surveillance. European Urology, 2016, 70, 365-371.	0.9	34
35	Reply to C. Rusner et al, L.C. Pagliaro et al, and K. Lu. Journal of Clinical Oncology, 2015, 33, 2326-2327.	0.8	0
36	Surgery After Relapse in Stage I Nonseminomatous Testicular Cancer. Journal of Clinical Oncology, 2015, 33, 2322-2322.	0.8	6

MADS AGERBAEK

#	Article	IF	CITATIONS
37	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncology, The, 2015, 16, 76-86.	5.1	323
38	Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. Acta Oncológica, 2015, 54, 1461-1466.	0.8	26
39	Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients. Psycho-Oncology, 2015, 24, 1174-1180.	1.0	34
40	Germ Cell Cancer and Multiple Relapses: Toxicity and Survival. Journal of Clinical Oncology, 2015, 33, 3116-3123.	0.8	29
41	Germ cell cancer and multiple relapses: Toxicity and survival Journal of Clinical Oncology, 2015, 33, 4533-4533.	0.8	0
42	A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a Surveillance Program. European Urology, 2014, 66, 1172-1178.	0.9	151
43	Surveillance for Stage I Nonseminoma Testicular Cancer: Outcomes and Long-Term Follow-Up in a Population-Based Cohort. Journal of Clinical Oncology, 2014, 32, 3817-3823.	0.8	189
44	No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis. Respiratory Medicine Case Reports, 2014, 12, 47-49.	0.2	2
45	Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder Journal of Clinical Oncology, 2014, 32, 4500-4500.	0.8	9
46	Renal impairment and late toxicity in germ-cell cancer (GCC) survivors Journal of Clinical Oncology, 2014, 32, 4555-4555.	0.8	0
47	Screening for carcinoma in situ (CIS) testis and occurrence of metachronous germ cell cancer (mGCC) Journal of Clinical Oncology, 2014, 32, 4554-4554.	0.8	0
48	A nationwide cohort study of surveillance for stage I seminoma Journal of Clinical Oncology, 2013, 31, 4502-4502.	0.8	9
49	Germ cell cancer (GCC): Long-term survival after treatment with bleomycin (B), etoposide (E), and cisplatin (P) in a large cohort Journal of Clinical Oncology, 2013, 31, 4533-4533.	0.8	4
50	Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer Journal of Clinical Oncology, 2013, 31, 252-252.	0.8	7
51	Expression of TIP60 (tatâ€interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatmentâ€specific outcome of localised invasive bladder cancer. BJU International, 2012, 110, E1228-36.	1.3	92
52	Focal S100A4 Protein Expression Is an Independent Predictor of Development of Metastatic Disease in Cystectomized Bladder Cancer Patients. European Urology, 2006, 50, 777-785.	0.9	26